TRD

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Venerdì, Maggio 3, 2024
FDA, Food, BDII, GHRS, Research, Psychiatry, New Drug Application, Insurance, TRD, Psychotherapy, IND, Patient, DSM-IV codes, Clinical trial, PD, G&A, Rat, Pharmaceutical industry

DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, May 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2024, and provided updates on its business.
  • We continue to expect GH001-PPD-203 completion and availability of top-line data in the third quarter of 2024.
  • R&D expenses were $8.7 million for the quarter ended March 31, 2024, compared to $7.3 million for same quarter in 2023.
  • G&A expenses were $2.9 million for the quarter ended March 31, 2024, compared to $3.1 million for the same quarter in 2023.

Toyota Establishes Hydrogen Headquarters to Accelerate Advancement of Fuel Cell Technology

Retrieved on: 
Mercoledì, Maggio 1, 2024
Hydrogen, TMNA, LPGA, National Renewable Energy Laboratory, FCD, Golden State, Toyota Motor Europe, Electricity, Research, Transport, TRD, Carbon, Fuel cell, PACCAR, CARB, Kenworth, PEM, Toyota Motor North America, Growth, Renewable energy

"Toyota has developed hydrogen fuel cell electric solutions for more than three decades, and we will continue to advance this scalable, zero-emission technology as part of our electrified portfolio," said Ted Ogawa, President and CEO, Toyota Motor North America.

Key Points: 
  • "Toyota has developed hydrogen fuel cell electric solutions for more than three decades, and we will continue to advance this scalable, zero-emission technology as part of our electrified portfolio," said Ted Ogawa, President and CEO, Toyota Motor North America.
  • "Renaming this facility as North American Hydrogen Headquarters represents our leadership in fuel cell development creating real-world products to help reduce carbon emissions."
  • Then, Toyota Motor Europe announced its own "Hydrogen Factory" with the aim to further grow Toyota's hydrogen business and stimulate wider roll-out of hydrogen ecosystems and infrastructure across Europe.
  • H2HQ will drive North American-led hydrogen initiatives and support the localization of global hydrogen-related technologies and products that include light-duty fuel cell applications, heavy-duty fuel cell opportunities, stationary fuel cell power generation, port vehicle applications and more.

Toyota Motor North America Announces New Leadership Structure

Retrieved on: 
Martedì, Aprile 30, 2024
TMNA, Information technology, Sustainability, Human resources, Research, Marketing, Business development, Research and development, Carbon footprint, TRD, Inclusion, Customer service, Regulatory affairs, Toyota Motor North America, Growth, Management

PLANO, Texas, April 30, 2024 /PRNewswire/ -- Toyota Motor North America (TMNA) today announced executive leadership changes designed to drive continued growth, advance our commitment to vehicle electrification, and prepare for the future of mobility.

Key Points: 
  • PLANO, Texas, April 30, 2024 /PRNewswire/ -- Toyota Motor North America (TMNA) today announced executive leadership changes designed to drive continued growth, advance our commitment to vehicle electrification, and prepare for the future of mobility.
  • Jack Hollis and Chris Reynolds are assigned new roles and will continue to report to Ted Ogawa, chief executive officer, TMNA.
  • Jack Hollis, executive vice president of TMNA adds the role of chief operating officer, TMNA reporting to Ted Ogawa, chief executive officer.
  • Chris Reynolds, executive vice president of TMNA adds the role of chief strategy officer, TMNA reporting to Ted Ogawa.

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Retrieved on: 
Mercoledì, Aprile 24, 2024
Patient, Safety, Pharmacokinetics, Atypical depression, SSRI, TRD, Entrepreneurship, Depression, Treatment, MADRS, Pharmaceutical industry

The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.

Key Points: 
  • The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.
  • Part 2 of the study will investigate a single dose of BPL-003 in patients who are currently on a course of SSRI antidepressants.
  • The first patient has been dosed in Part 2 of the study and initial results are expected in H1 2025.
  • Initial data showed that a single dose of BPL-003 induced a rapid antidepressant response1 in 55% of patients on the day after dosing.

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Retrieved on: 
Mercoledì, Aprile 17, 2024
Safety, Pharmacokinetics, Atypical depression, EDI, TRD, Entrepreneurship, Patient, Treatment, PD, Journal, Pharmaceutical industry

Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours.

Key Points: 
  • Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours.
  • NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.
  • Participants across seven cohorts were given either a single dose of BPL-003 between 1 mg to 12 mg or a placebo.
  • Commenting on the publication, Florian Brand, CEO and Co-Founder of atai, said: “We are pleased by the publication of the BPL-003 Phase 1 data in the Journal of Psychopharmacology, a well-regarded, peer-reviewed journal.

Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression

Retrieved on: 
Giovedì, Aprile 25, 2024
FDA, Brain, Yale University, Safety, Food, TRD, Therapy, Psychiatry, Patient, Freedom, SAN, Pharmaceutical industry

Freedom Bio will initiate its Phase 2a clinical trial (the "Study") in the first half of this year.

Key Points: 
  • Freedom Bio will initiate its Phase 2a clinical trial (the "Study") in the first half of this year.
  • This milestone marks a significant step forward in the development of FREE001, which has the potential to address a critical unmet medical need in patients suffering from TRD.
  • FREE001 builds on new ideas about brain mechanisms that limit the duration of ketamine efficacy.
  • Extending the duration and perhaps magnitude of ketamine efficacy could improve the safety, reduce patient burden of care, and expand access to this important treatment."

TOYOTA NAMED OFFICIAL VEHICLES OF WORLD WIDE TECHNOLOGY RACEWAY

Retrieved on: 
Mercoledì, Aprile 24, 2024
WWTR, Social media, Toyota, NASCAR Craftsman Truck Series, Partnership, TRD, NASCAR, Gateway Motorsports Park, Toyota Motor North America, Toyota Camry, Automotive industry

MADISON, Ill., April 24, 2024 /PRNewswire/ -- Toyota cars and trucks will lead the fields at the upcoming NASCAR race weekend at World Wide Technology Raceway (WWTR), signaling the first-ever automotive manufacturer partnership for the 700-acre multi-purpose racing facility. WWTR also announced that Toyota has renewed their race entitlement for the NASCAR CRAFTSMAN Truck Series Toyota 200, scheduled for June 1.

Key Points: 
  • "We are proud to name Toyota as the official vehicle provider of World Wide Technology Raceway," said Curtis Francois, WWTR owner and CEO.
  • "Toyota is pleased to be a big part of the race weekend at World Wide Technology Raceway," said Paul Doleshal, General Manager, Motorsports, Toyota Motor North America.
  • "On behalf of the St. Louis area Toyota Dealers, we are thrilled to join forces with World Wide Technology Raceway.
  • For tickets and more information, call World Wide Technology Raceway at (618) 215-8888, visit WWTRaceway.com or follow @WWTRaceway on social media.

2025 Toyota 4Runner Refines Adventure Ready Heritage

Retrieved on: 
Mercoledì, Aprile 10, 2024
Land cruiser, ARB, Radar, Nickel–metal hydride battery, Signature, Corrosion, Tundra, Old, Qi, AC, Control, Perforation, Beyond Zero, Blind spot monitor, OME, MID, Android, Torque, 4Runner, Traction, TRD, PDA, HAC, TNGA-F, Lane departure warning system, SAN, Safety, Mirai, RIGID, Carbon, DNA, BSM, Multimedia, TSS, Sequoia, Sale, Adaptive cruise control, BEV, SR5, Smart key, MAX, Roadside assistance, Road

The all-new 2025 Toyota 4Runner stays true to its original concept, as an extremely capable, dynamic, and durable off-roader and will continue to provide owners a window to bigger worlds.

Key Points: 
  • The all-new 2025 Toyota 4Runner stays true to its original concept, as an extremely capable, dynamic, and durable off-roader and will continue to provide owners a window to bigger worlds.
  • The 2025 4Runner will be built in Toyota Motor Corporation's Tahara plant in Japan and will arrive in the U.S. in the fall of 2024.
  • The 2025 4Runner introduces its first-ever Platinum grade which offers customers a high-end, luxury experience with all the capability you expect in a 4Runner.
  • All 2025 4Runner models come standard with Toyota Safety Sense 3.0, Toyota's suite of active safety and convenience systems.

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Retrieved on: 
Giovedì, Marzo 28, 2024
Research, Depression, Congress, PD, Patient, OUD, CIAS, Sale, G&A, DMT, Șaeș, Pivotal, Psilocybin, Atai, TRD, Investment, Ibogaine, Pharmacokinetics, Safety, PTSD, OTF, Pharmaceutical industry

“In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.

Key Points: 
  • “In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc., streamlining clinical, general and administrative operations.
  • atai realized operational efficiencies by simplifying and optimizing its organizational structure in line with its revised business and pipeline priorities.
  • In August 2023, the Phase 1 study results demonstrated that 9 mg/kg of oral ibogaine leads to robust psychedelic experiences.

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Retrieved on: 
Giovedì, Marzo 28, 2024
Patient, Chairperson, CNS, Mental health, Innovation, CMPS, Psilocybin, TRD, Johnson & Johnson, Operation, Pain, KCL, Frustration, J&J, Food, Nursing

David Norton, lead independent director on the Compass board of directors, will become interim chair.

Key Points: 
  • David Norton, lead independent director on the Compass board of directors, will become interim chair.
  • Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle.
  • “When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways.
  • He has been a member of the Compass board of directors since 2018, serving as lead independent director.